Abstract: The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Abstract: The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the ? chain; R9 of the ? chain; Y10 of the ? chain; T24 of the ? chain; V19 of the ? chain; T20 of the ? chain; M50 of the ? chain; T5 of the ? chain; Q8 of the ? chain; S86 of the ? chain; F39 of the ? chain; D55 of the ? chain; R43 of the ? chain; A66 of the ? chain; V19 of the ? chain; L21 of the ? chain; L103 of the ? chain; T3 of the ? chain; S7 of the ? chain; P9 of the ? chain; M11 of the ? chain; A16 of the ? chain; T18 of the ? chain; L21 of the ? chain; S22 of the ? chain; D26 of the ? chain; F40 of the ? chain; S47 of the ? chain; R48 of the ? chain; Q49 of the ? chain; I51 of the ? chain; L52 of the ? chain; V53 of the ? chain; T67 of the ? chain; E68 of the ? chain; N74 of the ? chain; F76 of the ? chain; N79 of the ? chain; Q81 of the ? chain; A83 of the ? chain; K90 of the ? chain; S92 of the ? chain; D93 of the ? chain; and M101 of the ? chain; wherein the at

Abstract: TCR The present invention relates to an engineered T cell receptor (TCR). In particular, the present invention relates to methods for expression of a TCR when expressed as an exogenous TCR, to methods for selecting a TCR with high cell surface expression when expressed as an exogenous TCR and to methods for identifying residues which contribute to the cell surface expression level of a TCR. The present invention also relates to an engineered TCR which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Abstract: The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Abstract: A method for increasing the cell surface expression and/or reducing mispairing of a TCR.

Abstract: The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the ? chain; R9 of the ? chain; Y10 of the ? chain; T24 of the ? chain; V19 of the ? chain; T20 of the ? chain; M50 of the ? chain; T5 of the ? chain; Q8 of the ? chain; S86 of the ? chain; F39 of the ? chain; D55 of the ? chain; R43 of the ? chain; A66 of the ? chain; V19 of the ? chain; L21 of the ? chain; L103 of the ? chain; T3 of the ? chain; S7 of the ? chain; P9 of the ? chain; M11 of the ? chain; A16 of the ? chain; T18 of the ? chain; L21 of the ? chain; S22 of the ? chain; D26 of the ? chain; F40 of the ? chain; S47 of the ? chain; R48 of the ? chain; Q49 of the ? chain; 151 of the ? chain; L52 of the ? chain; V53 of the ? chain; T67 of the ? chain; E68 of the ? chain; N74 of the ? chain; F76 of the ? chain; N79 of the ? chain; Q81 of the ? chain; A83 of the ? chain; K90 of the ? chain; S92 of the ? chain; D93 of the ? chain; and M101 of the ? chain; wherein the at

Abstract: The present invention relates to a natural killer T (NKT) cell comprising an engineered T cell receptor (TCR) which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: TCR The present invention relates to an engineered T cell receptor (TCR). In particular, the present invention relates to methods for expression of a TCR when expressed as an exogenous TCR, to methods for selecting a TCR with high cell surface expression when expressed as an exogenous TCR and to methods for identifying residues which contribute to the cell surface expression level of a TCR. The present invention also relates to an engineered TCR which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the ? chain; R9 of the ? chain; Y10 of the ? chain; T24 of the ? chain; V19 of the ? chain; T20 of the ? chain; M50 of the ? chain; T5 of the ? chain; Q8 of the ? chain; S86 of the ? chain; F39 of the ? chain; D55 of the ? chain; R43 of the ? chain; A66 of the ? chain; V19 of the ? chain; L21 of the ? chain; L103 of the ? chain; T3 of the ? chain; S7 of the ? chain; P9 of the ? chain; M11 of the ? chain; A16 of the ? chain; T18 of the ? chain; L21 of the ? chain; S22 of the ? chain; D26 of the ? chain; F40 of the ? chain; S47 of the ? chain; R48 of the ? chain; Q49 of the ? chain; I51 of the ? chain; L52 of the ? chain; V53 of the ? chain; T67 of the ? chain; E68 of the ? chain; N74 of the ? chain; F76 of the ? chain; N79 of the ? chain; Q81 of the ? chain; A83 of the ? chain; K90 of the ? chain; S92 of the ? chain; D93 of the ? chain; and M101 of the ? chain; wherein the at

Abstract: The present invention provides a method for increasing the sensitivity of a T cell expressing a cell-surface antibody to a target antigen, which comprises the step of lowering the affinity of the antibody to the target antigen by at least 100-fold. The invention also provides chimeric antigen receptor comprising an antibody domain having an affinity for antigen in the range 100-1 ?M, its encoding nucleic acid sequence and uses thereof.

Abstract: The present invention provides a method for increasing the sensitivity of a T cell expressing a cell-surface antibody to a target antigen, which comprises the step of lowering the affinity of the antibody to the target antigen by at least 100-fold. The invention also provides chimeric antigen receptor comprising an antibody domain having an affinity for antigen in the range 100-1 ?M, its encoding nucleic acid sequence and uses thereof.